These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11453308)

  • 1. Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer.
    Neber DW; Roe AL
    Sci Total Environ; 2001 Jul; 274(1-3):93-102. PubMed ID: 11453308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants.
    Nebert DW
    Clin Chem Lab Med; 2000 Sep; 38(9):857-61. PubMed ID: 11097340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of individual susceptibility in cancer burden related to environmental exposure.
    Bartsch H; Hietanen E
    Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):569-77. PubMed ID: 8781385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics: detecting sensitive populations.
    Shields PG
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):81-7. PubMed ID: 7737047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Environmental and chemical carcinogenesis.
    Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
    Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues.
    Nebert DW; Ingelman-Sundberg M; Daly AK
    Drug Metab Rev; 1999 May; 31(2):467-87. PubMed ID: 10335448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicogenetic profile and cancer risk in Lebanese.
    Dhaini HR; Kobeissi L
    J Toxicol Environ Health B Crit Rev; 2014; 17(2):95-125. PubMed ID: 24627976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response.
    Autrup H
    Mutat Res; 2000 Jan; 464(1):65-76. PubMed ID: 10633178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals.
    Wolf CR
    IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis.
    Gonzalez FJ; Kimura S
    Cancer Lett; 1999 Sep; 143(2):199-204. PubMed ID: 10503904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
    Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
    Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility.
    Hatagima A
    Cad Saude Publica; 2002; 18(2):357-77. PubMed ID: 11923879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and Phase II enzyme polymorphisms and childhood cancer.
    Swinney R; Hsu S; Tomlinson G
    J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer.
    Kiyohara C
    J Epidemiol; 2000 Sep; 10(5):349-60. PubMed ID: 11059519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Individual susceptibility to occupational carcinogens: the evidence from biomonitoring and molecular epidemiology studies].
    Pavanello S; Clonfero E
    G Ital Med Lav Ergon; 2004; 26(4):311-21. PubMed ID: 15584438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary polymorphisms of human drug metabolizing enzymes and cancer susceptibility.
    Gonzalez FJ
    Birth Defects Orig Artic Ser; 1990; 26(1):17-42. PubMed ID: 2224077
    [No Abstract]   [Full Text] [Related]  

  • 20. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer.
    Druesne-Pecollo N; Tehard B; Mallet Y; Gerber M; Norat T; Hercberg S; Latino-Martel P
    Lancet Oncol; 2009 Feb; 10(2):173-80. PubMed ID: 19185835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.